drugset / Trial / NCT01033149

N-acetylcysteine in the Treatment of Bulimia Nervosa

NCT01033149

NaSingle-groupOpen-labelTreatment

Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of N-acetylcysteine (NAC) in the treatment on bulimia nervosa.

Timeline

Start
2009-12
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 1200 mg
Subject N-acetylcysteine Small molecule 2400 mg

Indications